ProfundBio (Suzhou) Co., Ltd., founded in 2018 and headquartered in Seattle, Washington, USA, is a developer of targeted therapeutic drugs for cancer patients.
The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/profoundbio.html
ProfundBio US Equities Encyclopedia
ProfundBio is a clinical companyBiotechnology Company, focusing on the development of new antibody therapy with cure potential for cancer patients.Based on the innovative technology platform, ProfundBio has developed a product line consisting of a variety of candidate drugs, which is currently in the discovery, preclinical development and clinical stages, targeting a variety of tumors.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/profoundbio.html
Based on the innovative proprietary technology platform developed internally, ProfundBio has developed a pipeline composed of a variety of antibody drug conjugates (ADC) candidate drugs. For solid tumors and blood malignancies, these drugs are in the stage of discovery, preclinical and clinical development.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/profoundbio.html
ProfundBio candidate product
1、Rinatabart Sesutecan (Rina-S, PRO1184)The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/profoundbio.html
Folate receptorα（Folate Receptor Alpha，FRα）It is overexpressed in many solid tumors but limited in normal tissues, so it is an attractive target of antibody drug conjugates (ADC).The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/profoundbio.html
Rina-S is composed of human monoclonal antibody, selectively binding human FRαIt is composed of a novel cleavable hydrophilic linker and a topoisomerase 1 inhibitor exatecan.Rina-S has antitumor activity in patients with endometrial cancer and ovarian cancer (SITC 2023) at well tolerated dose levels.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/profoundbio.html
The first phase 1/2 study for patients with advanced solid tumors is currently being recruited (NCT 05579366).The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/profoundbio.html
2、PRO1160The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/profoundbio.html
CD70 is a cell surface antigen, which is often overexpressed in a variety of blood and solid malignancies, but not in normal tissues.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/profoundbio.html
PRO1160 consists of a human monoclonal antibody that selectively binds to CD70, a novel cleavable hydrophilic connector, and a topoisomerase 1 inhibitor payload exatecan.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/profoundbio.html
PRO1160 shows promising preclinical characteristics in PK, efficacy and tolerance, supporting its further development for various cancers, including renal cell carcinoma (RCC), nasopharyngeal carcinoma (NPC) and non Hodgkin's lymphoma (NHL).
ProfundBio financing encyclopedia
In February 2021, ProfundBio completed the seed round financing of $10 million led by K2VC, and Chang'an Capital followed.
In July 2021, ProfundBio will completeLilly Asia VenturesAnd the round A financing of $55 million led by LYFE Capital,Sequoia CapitalChina, K2VC, Gaorong Capital, Oriza Holdings, etc.
In June 2022, ProfundBio will completeSequoia CapitalChina led the US $70 million A+round of financing, and Lilly Asia Ventures, LYFE Capital, K2VC, Oriza Holdings, etc.
In February 2024, ProfundBio completed the round B financing of $112 million led by Ally Bridge Group, Lilly Asia VenturesOrbiMed、T. Rowe Price、RA Capital Management, Janus Henderson Investors, etc.
On April 3, 2024,GenmabHe said that he agreed to invest 1.8 billion dollars to acquire ProfundBio, a biotechnology start-up, to develop antibody drug conjugates (ADC).ProfundBio's product portfolio includes Rina-S, a new type of ADC, which is said to be a potential best in class drug.The drug is designed to target the expression of folate receptorsαProtein tumors are currently in the phase II test of ovarian cancer and some other types of solid tumors.
In May 2024, by opening an account at American Stock House and merging 10000 Hong Kong dollars (HKD) into Long Bridge, you can get a lifetime free commission of [Hong Kong shares+American shares], and can also get up to 1100 Hong Kong dollars of stock certificates+an additional 88 yuanJD.COMCard (exclusive)+RMB 100 rebate (exclusive).Exclusive to American Stock House customers.Click to view details!
two hundred and forty-nine million three hundred and forty-two thousand five hundred and nineteen
WeChat official account: Encyclopedia of US and Hong Kong stocks
WeChat search: mggbkqs
mggbkqs
This article is written byOriginated by American Stock HousePublished on April 4, 2024 at 17:17:07
Original articles of American Stock House,Unauthorized reproduction is strictly prohibited。This article and all articles on this website are intended for information dissemination and sharing, and do not constitute an invitation, solicitation, suggestion, opinion or any guarantee for any securities, financial products or instruments. American Stock House does not endorse any companies, securities firms or financial products.There are risks in investment. Customers should weigh the risks they can bear and make investment judgments independently. If you have any questions, please consult independent professionals.Disclaimer
On April 3, 2024, Genmab A/S (NASDAQ code: GMAB) and ProfundBio, Inc. jointly announced that the two companies had reached a final agreement, and Genmab would acquire ProfundBio through an all cash transaction.Pufang Biology is an unlisted biotechnology company at the clinical stage, focusing on the development of new generation ADC drug pipeline and platform technology to treat tumors, including ovarian cancer.Genmab's acquisition consideration for Pfizer Biotech is US $1.8 billion, which will be paid in cash when the transaction is completed.
Through this transaction, Genmab will obtain all the rights and interests of three clinical products and several preclinical products of Pratt&Whitney Biotech;These include Rina-S, a new generation of toxin targeting folate receptor alpha (FRα）ADC of.Rina-S is currently in the phase 1/2 clinical trial for ovarian cancer and other solid tumors.In addition, the combination of the innovative ADC technology platform of Pufang Biology and the proprietary antibody technology platform of Genmab will bring new opportunities for developing innovative drugs, bringing revolutionary treatment plans to tumor patients and significantly improving their quality of life.
Rina-S will help Genmab strengthen its layout in the field of gynecological tumors, and provide a solid foundation for expanding to a broader field of solid tumors.As the best potential target, compared with the first generation targeted FRαRina-S is committed to significantly expanding the potential beneficiaries.Based on the existing positive clinical data of Rina-S, Genmab plans to further expand the clinical research and development plan of Rina-S in ovarian cancer and other solid tumors.In January 2024, the US FDA granted Rina-S fast track qualification for the treatment of FR expressionαOf patients with platinum resistant ovarian cancer.
